Biosimilar Red Tape Elimination Act

U.S. Congress · S1954 · Floor

What the bill says

S1954 · U.S. Congress · Floor

Introduced 2025-06-04. Latest action: Placed on Senate Legislative Calendar under General Orders. Calendar No. 521.

View on Congress.gov →

Sponsors

Text versions

  • Introduced in Senate — 2025-06-04 — XML
  • Reported to Senate — 2026-07-27 — XML

What analysts say

No nonpartisan analysis on file for this measure yet.

What politicians say

No linked claims or utterances yet — no one on record has cited this measure to justify a public argument.

Action History

DateAction
2026-07-27Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
2026-07-27Placed on Senate Legislative Calendar under General Orders. Calendar No. 521.
2026-06-17Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
2025-06-04Introduced in Senate
2025-06-04Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Lobbying on this bill

Showing 25 of 60 bill mentions.

Honesty note: each filer below disclosed lobbying on this bill — that much the filing tells us. But the dollar figure is their total lobbying spend for the whole quarter across all their issues, not the amount spent on this bill, and the filing never says whether they supported or opposed it.

Registrant (lobbying firm)ClientPeriodReported quarterly amountExtraction
BLUE CROSS AND BLUE SHIELD OF KANSAS, INC. BLUE CROSS AND BLUE SHIELD OF KANSAS INC Q2 2026 $10,000 Explicit
ASSOCIATION FOR CLINICAL ONCOLOGY ASSOCIATION FOR CLINICAL ONCOLOGY Q2 2026 $480,000 Explicit
GSK (FKA GLAXOSMITHKLINE INC.) GSK (FKA GLAXOSMITHKLINE INC.) Q2 2026 $890,000 Explicit
PRIME THERAPEUTICS PRIME THERAPEUTICS Q2 2026 $100,000 Explicit
MEHLMAN CONSULTING, INC. ASSOCIATION OF ACCESSIBLE MEDICINES Q2 2026 $60,000 Explicit
BCBSM, INC. BCBSM INC Q2 2026 $28,000 Explicit
TIBER CREEK GROUP AMGEN INC Q2 2026 $60,000 Explicit
THORN RUN PARTNERS THE BIOSIMILARS FORUM Q2 2026 $100,000 Explicit
APOTEX CORP. APOTEX CORP. Q2 2026 $730,000 Explicit
GUIDEWELL MUTUAL HOLDING CORPORATION GUIDEWELL MUTUAL HOLDING CORPORATION Q2 2026 $20,000 Explicit
CAMBIA HEALTH SOLUTIONS CAMBIA HEALTH SOLUTIONS Q2 2026 $700,000 Explicit
FIERCE GOVERNMENT RELATIONS ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA) Q2 2026 $60,000 Explicit
BLUE CROSS AND BLUE SHIELD ASSOCIATION BLUE CROSS AND BLUE SHIELD ASSOCIATION Q2 2026 $990,000 Explicit
AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS Q2 2026 $260,000 Explicit
AVENUE SOLUTIONS AMGEN, INC. Q2 2026 $50,000 Explicit
SMALL BUSINESS & ENTREPRENEURSHIP COUNCIL (SBE COUNCIL) SMALL BUSINESS & ENTREPRENEURSHIP COUNCIL (SBE COUNCIL) Q2 2026 $45,000 Explicit
MEHLMAN CONSULTING, INC. THE CAMPAIGN FOR SUSTAINABLE RX PRICING Q2 2026 $90,000 Explicit
VIZIENT, INC. VIZIENT INC Q2 2026 $320,000 Explicit
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA Q2 2026 $7,360,000 Explicit
JOHNSON & JOHNSON SERVICES, INC. JOHNSON & JOHNSON SERVICES INC Q2 2026 $1,440,000 Explicit
AMGEN, INC. AMGEN INC Q2 2026 $2,440,000 Probable
FRESENIUS KABI USA LLC FRESENIUS KABI USA LLC Q2 2026 $580,000 Explicit
FRESENIUS KABI USA LLC FRESENIUS KABI USA LLC Q2 2026 $580,000 Explicit
BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. BLUE CROSS AND BLUE SHIELD OF FLORIDA INC Q2 2026 $80,000 Explicit
THE NICKLES GROUP, LLC AMGEN Q2 2026 $60,000 Explicit

Source: Senate LDA filings.